Diamyd Medical AB Has Treated Half of the Patients in European Registration Study

STOCKHOLM, Sweden, May 14, 2009 (GLOBE NEWSWIRE) -- Diamyd Medical reported today that 166 out of a total of 320 patients, who are part of the European Phase III study of the Diamyd(r) diabetes vaccine, have now been included in the study. Discussions with regulatory agencies are ongoing regarding how the brisk rate of recruitment in Europe can best be utilized in Diamyd's global Phase III program. The company estimates that the program will be fully recruited during 2009.

Back to news